Related Experiment Videos
Parkinson syndrome as a manifestation of mitochondriopathy
1Ludwig Boltzmann Institute for Epilepsy and Neuromuscular Disorders, Postfach 348, 1180 Vienna, Austria. duarte@jet2web.cc
Objectives:
Although there is growing evidence for a relation between Parkinson syndrome (PS) and mitochondriopathy (MCP), little is known about the frequency of PS in MCP.
Material And Methods:
This study assessed the frequency of PS in patients with MCP, the phenotype of these patients, and their response to anti-Parkinson medication, during a 1-year period.
Results:
Between April 1999 and March 2000 PS was diagnosed in nine of 76 patients with MCP (12%). The frequency of MCP among 144 patients with PS attending the department during the investigational period was 6.3%. Systems most frequently affected by the MCP in the nine patients were the peripheral nervous system, central nervous system, endocrinium, heart, intestines, eyes, ears and kidneys. PS in MCPs responded well to amantadine, L-DOPA, dopamine agonists and catechole-o-methyl-transferase inhibitors.
Conclusion:
Twelve per cent of the patients with MCP have phenotypic features of PS and 6% of the patients with PS have features of MCP. MCP patients with PS frequently show multisystem involvement. PS in MCP responds well to anti-Parkinson medication.
Insights
Parkinson syndrome (PS) affects 12% of mitochondriopathy (MCP) patients, while 6% of PS patients show MCP features. Both conditions benefit from Parkinson
Area of Science:
- Neurology
- Mitochondrial Diseases
- Movement Disorders
Background:
- Growing evidence links Parkinson syndrome (PS) and mitochondriopathy (MCP).
- The prevalence of PS in MCP patients remains largely unknown.
- Understanding this relationship is crucial for comprehensive patient care.
Purpose of the Study:
- To determine the frequency of PS in patients diagnosed with MCP.
- To characterize the clinical phenotype of MCP patients with PS.
- To evaluate the efficacy of anti-Parkinsonian medications in this cohort.
Main Methods:
- Prospective study over a 1-year period.
- Assessed PS diagnosis in 76 MCP patients.
- Evaluated MCP prevalence in 144 PS patients.
Main Results:
- PS was diagnosed in 12% of MCP patients (9 out of 76).
- MCP was identified in 6.3% of PS patients (144 total).
- MCP patients with PS exhibited multisystem involvement and responded well to standard anti-Parkinsonian drugs.
Conclusions:
- A significant percentage of MCP patients exhibit PS features, and vice versa.
- Multisystemic involvement is common in MCP patients with PS.
- Anti-Parkinsonian therapies are effective for PS in the context of MCP.